#### **DATA USE CERTIFICATION AGREEMENT**

This Data Use Certification (DUC) Agreement outlines the terms of use for requested controlled-access datasets maintained in NIH-designated data repositories under the NIH Genomic Data Sharing Policy (e.g., the NIA Genetics of Alzheimer's Disease Data Storage Site (NIAGADS), a NIH controlled-access data repository). The Addendum to this Agreement outlines additional terms and information which are specific to each requested dataset such as:

- Data Use Limitation(s)
- Sponsoring NIH Institute or Center
- Responsible Data Access Committee
- Study Description
- Suggested Acknowledgement Statement

#### **INTRODUCTION AND STATEMENT OF POLICY**

The National Institutes of Health (NIH) <u>Genomic Data Sharing (GDS) Policy</u> expects investigators generating large-scale human genomic data as well as relevant associated data to submit these data to a NIH-designated data repository. Respect for, and protection of the interests of, research participants are a key tenet of the GDS Policy and fundamental to NIH's stewardship of human genomic data. As such, access to controlled-access human genomic data will be provided only to research investigators who, along with their institutions, agree to meet the expectations and terms of access detailed below and to use the data according to participant informed consent, actualized as applicable Data Use Limitations established by the <u>Submitting Institution</u> through the <u>Institutional Certification</u>.

The National Institute on Aging (NIA) has established the NIA Genetics of Alzheimer's Disease Data Storage Site (NIAGADS) as a resource to serve as a repository for many types of data generated by NIA supported grants and cooperative agreements and/or NIA funded biological samples. NIAGADS operates under the NIH Genomic Data Sharing Policy (GDS) and the NIA Genetics of Alzheimer's Disease Data Sharing Policy. Because the human genomic and phenotypic data contained in NIAGADS is, in some instances, potentially sensitive information, e.g., data related to the presence or risk of developing Alzheimer's Disease and related neurodegenerative disorders, and information regarding family relationships or ancestry, data must be shared in a manner consistent with the research participants' informed consent, and the confidentiality of the data and the privacy of participants must be protected.

Definitions of the underlined terminology in this document are found in section 14.

The parties to this Agreement include: the <u>Principal Investigator</u> (PI) requesting access to controlled-access genomic and associated data (an "<u>Approved User</u>"), the <u>PI</u>'s home institution (the "<u>Requester</u>") as represented by the <u>Institutional Signing Official</u>, and NIAGADS. The effective date of this Agreement shall be the data access request (<u>DAR</u>) Approval Date, as specified in the NIAGADS approval notification.

## **TERMS OF ACCESS**

#### 1. Research Use

The <u>Requester</u> agrees that if access is approved, (1) the <u>PI</u> named in the <u>DAR</u> and (2) those named in the "Senior/Key Person Profile" section of the <u>DAR</u>, including the <u>Information Technology Director</u> and

any trainee, employee, or contractor¹ working on the proposed research project under the direct oversight of these individuals, shall become <u>Approved Users</u> of the requested dataset(s). The <u>Requester</u> and <u>Approved Users</u> acknowledge responsibility for ensuring the review and agreement to the terms within this Agreement and the appropriate research use of controlled-access data obtained through the attached <u>DAR</u> and any <u>Data Derivatives</u> of controlled-access datasets by research staff associated with any approved project, subject to applicable laws and regulations. Research use will occur solely in connection with the approved research project described in the <u>DAR</u>, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). The <u>Requester</u> further certifies that the Research Use Statement's description of the proposed research is truthful and accurate.

If the <u>DAR</u> process expects a Cloud Use Statement for investigators interested in using <u>Cloud Computing</u>, investigators must provide a Cloud Use Statement about the <u>Cloud Service Provider (CSP)</u> and/or <u>third-party IT system</u> and agree to secure the data according to the <u>NIH Security Best Practices for Users of Controlled-Access Data</u>. The Cloud Use Statement should at least state the name of the <u>CSP</u> and/or <u>third-party IT system</u>, the security standard, and how the <u>CSP</u> and/or <u>third-party IT system</u> will be used to carry out the work described in the Research Use Statement. If applicable, the investigator should describe the role of any <u>Collaborators</u> in using the <u>CSP</u> and/or <u>third-party IT system</u>. If the <u>Approved User(s)</u> plans to collaborate with investigators outside the <u>Requester</u>, the investigators at each external site must submit an independent <u>DAR</u> using the same project title and Research Use Statement, and if the <u>DAR</u> process expects when using the cloud, a Cloud Use Statement. New uses of these data outside those described in the <u>DAR</u> will require submission of a new <u>DAR</u>; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting <u>Requester</u>, <u>Collaborators</u> from the <u>Requester</u>, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of **one (1) year**, with the option to renew access or close-out a project at the end of that year.

<u>Submitting Investigator(s)</u>, or their <u>Collaborators</u>, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval, as applicable, and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the <u>DAR</u>.

# 2. Requester and Approved User Responsibilities

The <u>Requester</u> agrees, through the submission of the <u>DAR</u>, that the <u>Approved Users</u> have reviewed and understand the principles for responsible use and data management of controlled-access data as defined in the GDS Policy and the <u>NIH Security Best Practices for Users of Controlled-Access Data</u>. The <u>Requester</u> and <u>Approved Users</u> acknowledge that the NIH (including NIH DACs) may reject <u>DARs</u>, request revisions to <u>DARs</u>, and terminate ongoing research described in the Research Use Statement if NIH assesses the project has significant potential to cause harm to research participants, their families,

<sup>&</sup>lt;sup>1</sup> If contractor services are to be utilized, the <u>PI</u> requesting the data must provide a brief description of the services that the contractor will perform for the <u>PI</u> (e.g., data cleaning services) in the research use statement of the <u>DAR</u>. The <u>PI</u> is expected to include in any contract agreement requirements that any of the contractor's employees who have access to the data adhere to the <u>NIH GDS Policy</u>, this <u>Data Use Certification Agreement</u>, and the <u>NIH Security Best Practices for Users of Controlled-Access Data</u>. Note that any scientific collaborators, including contractors, who are not at the <u>Requester</u> must submit their own <u>DAR</u>. These requirements apply whether the contractor carries out the work at the <u>PI</u>'s facility or at the contractor's facility.

groups and populations of which they are a part, or the national security of the United States, or for any reason at NIH's discretion. The Requester and Approved Users further acknowledge that they are responsible for ensuring that all uses of the data are consistent with national, Tribal, and state laws and regulations, as appropriate, as well as relevant institutional policies and procedures for managing controlled-access data. The Requester and Approved Users agree that in using the data, they are not aware of significant potential for the research to cause harm to participants, their families, groups and populations of which they are a part (e.g., from stigma associated with the research results), or the national security of the United States. The Requester and Approved Users agree that in using the data, if they become aware of significant potential for the research to cause harm to participants, their families, groups and populations of which they are a part, or the national security of the United States that they will notify NIH within 24 hours. The Requester certifies that the PI is in good standing (i.e., no known sanctions) with the institution, relevant funding agencies, and regulatory agencies and is eligible to conduct independent research (i.e., is not a postdoctoral fellow, student, or trainee). The Requester and any Approved Users may use the dataset(s) only in accordance with the parameters described on the study page and in the Addendum to this Agreement for the appropriate research use, as well as any limitations on such use of the dataset(s) as described in the DAR, and as required by law.

Through the submission of this <u>DAR</u>, the <u>Requester</u> and <u>Approved Users</u> acknowledge receiving and reviewing a copy of the Addendum which includes Data Use Limitation(s) for requested controlled-access data. The <u>Requester</u> and <u>Approved Users</u> agree to comply with the terms listed in the Addendum.

Through submission of the <u>DAR</u>, the <u>PI</u> and <u>Requester</u> agree to submit a <u>Project Renewal</u> or <u>Project Close-out</u> prior to the expiration date of the one (1) year data access period. The <u>PI</u> also agrees to submit an annual <u>Progress Update</u> prior to the one (1) year anniversary of the project, as described under *Research Use Reporting* (Term 11) below.

By approving and submitting the attached <u>DAR</u>, the <u>Institutional Signing Official</u> provides assurance that relevant institutional policies and applicable local, state, Tribal, and federal laws and regulations, as applicable, have been followed, including IRB approval, if required. <u>Approved Users</u> may be required to have IRB approval if they have access to personal identifying information for research participants in the original study at their institution, or through their <u>Collaborators</u>. The <u>Institutional Signing Official</u> also assures, through the approval of the <u>DAR</u>, that other institutional departments with relevant authorities (e.g., those overseeing human subjects research, information technology, technology transfer) have reviewed the relevant sections of the NIH GDS Policy and the associated procedures and are in agreement with the principles defined.

The <u>Requester</u> acknowledges that controlled-access datasets subject to the NIH GDS Policy may be updated to exclude or include additional information. Unless otherwise indicated, all statements herein are applicable to the access and use of all versions of these datasets.

## 3. Public Posting of Approved Users' Research Use Statement

The <u>PI</u> agrees that information about themselves and the approved research use will be posted publicly on the NIAGADS website. The information includes the <u>PI</u>'s name and <u>Requester</u>, project name, Research Use Statement, and a Non-Technical Summary of the Research Use Statement. In addition, and if applicable, this information may include the Cloud Use Statement and name of the <u>CSP</u> and/or <u>third-party IT system</u>. Citations of publications resulting from the use of controlled-access data obtained through this <u>DAR</u> may also be posted on the NIAGADS website.

#### 4. Non-Identification

Approved Users agree to make no attempt to identify or contact, either directly or indirectly, individual participants or their families. Approved Users agree not to use the requested datasets, either alone or in concert with any other information, to identify or contact individual participants from whom data and/or samples were collected. Approved Users also agree not to generate information (e.g., facial images or comparable representations) that could allow the identities of research participants to be readily ascertained. These provisions do not apply to research investigators operating with specific IRB approval, pursuant to 45 CFR 46, to contact individuals within datasets or to obtain and use identifying information under an IRB-approved research protocol. All investigators including any Approved User conducting "human subjects research" within the scope of 45 CFR 46 must comply with the requirements contained therein.

## 5. Certificate of Confidentiality

Effective March 15, 2017, the Certificate of Confidentiality (Certificate) issued for the NIA Genetics of Alzheimer's Disease Data Storage Site (NIAGADS) is subject to the requirements of section 301(d) of the Public Health Service Act (42 U.S.C. 241(d)). Moreover, as of October 1, 2017 NIAGADS is required to adhere to the NIH Policy for Issuing Certificates of Confidentiality (NOT-OD-17-109). Therefore, Approved Users of NIAGADS, whether or not funded by the NIH, who access a copy of information protected by a Certificate held by NIAGADS, are also subject to the requirements of the Certificate of Confidentiality and subsection 301(d) of the Public Health Service Act.

Under Section 301(d) of the Public Health Service Act and the *NIH Policy for Issuing Certificates of Confidentiality*, recipients of a Certificate of Confidentiality shall not:

- Disclose or provide, in any Federal, State, or local civil, criminal, administrative, legislative, or
  other proceeding, the name of such individual or any such information, document, or
  biospecimen that contains identifiable, sensitive information about the individual and that was
  created or compiled for purposes of the research, unless such disclosure or use is made with the
  consent of the individual whom the information, document, or biospecimen pertains; or
- Disclose or provide to any other person not connected with the research the name of such an
  individual or any information, document, or biospecimen that contains identifiable, sensitive
  information about such an individual and that was created or compiled for purposes of the
  research.

# Disclosure is permitted only when:

- Required by Federal, State, or local laws (e.g., as required by the Federal Food, Drug, and
  Cosmetic Act, or state laws requiring the reporting of communicable diseases to State and local
  health departments), excluding instances of disclosure in any Federal, State, or local civil,
  criminal, administrative, legislative, or other proceeding;
- Necessary for the medical treatment of the individual to whom the information, document, or biospecimen pertains and made with the consent of such individual;
- Made with the consent of the individual to whom the information, document, or biospecimen pertains; or
- Made for the purposes of other scientific research that is in compliance with applicable Federal regulations governing the protection of human subjects in research.

For more information see: Certificates of Confidentiality (CoC) | Grants & Funding

# 6. Non-Transferability

The <u>Requester</u> and <u>Approved Users</u> agree not to distribute controlled-access data and any <u>Data</u> <u>Derivatives</u> to any entity or individual not identified in the approved request without appropriate written approvals from the NIH. If the <u>Approved Users</u> are provided access to controlled-access datasets subject to the NIH GDS Policy for inter-institutional collaborative research described in the Research Use Statement of the <u>DAR</u>, and all members of the collaboration are also <u>Approved Users</u> through their home institution(s), data obtained through the attached <u>DAR</u> may be securely transmitted within the collaborative group. Each <u>Approved User</u> will secure the data according to the <u>NIH Security Best Practices for Users of Controlled-Access Data</u>, the terms of this Agreement, and the <u>Requester</u>'s IT security requirements and policies.

<u>Requester</u> and <u>Approved Users</u> agree that controlled-access datasets obtained through the attached <u>DAR</u> and any <u>Data Derivatives</u> of controlled-access datasets, in whole or in part, may not be sold to any individual at any point in time for any purpose.

The <u>PI</u> agrees that if they change institutions during the approved access period, they will complete the <u>Project Close-out</u> process (See Term 13 for more details) before moving to their new institution. A new <u>DAR</u>, in which the new <u>Requester</u> agrees to the <u>Data Use Certification Agreement</u> and the <u>Genomic Data User Code of Conduct</u>, must be approved by the NIAGADS Data Use Committee (NIAGADS DUC) and the NIAGADS ADRD Data Access Committee (NADAC) before controlled-access data may be re-accessed.

## 7. Data Security and Unauthorized Data Release

The <u>Requester</u> and <u>Approved Users</u> acknowledge NIH's expectation that they have reviewed and agree to manage the requested controlled-access data and any <u>Data Derivatives</u> according to NIH's expectations set forth in the current <u>NIH Security Best Practices for Users of Controlled-Access Data</u> and the <u>Requester</u>'s IT security requirements and policies.

The <u>Requester</u> and <u>PI</u> agree to notify NIAGADS, the NIH Incident Response Team, and NIH Office of Extramural Research Data Sharing Policy Implementation (OER/DSPI) Team of any unauthorized data sharing, breaches of data security, or inadvertent data releases that may compromise data confidentiality within 24 hours of when the incident is identified. For NIAGADS, notifications can be sent to <u>niagads@pennmedicine.upenn.edu</u>. For the NIH Incident Response Team notifications can be made by phone (301) 496-HELP (4357); Toll Free Number: (866) 319-4357or TTY: (301) 496-8294 and can also be sent by email to <u>NIHInfoSec@nih.gov</u> or via the Report an Incident Link: <a href="https://irtportal.ocio.nih.gov/">https://irtportal.ocio.nih.gov/</a>. For OER/DSPI Team, notifications can be sent to DMI OER@mail.nih.gov.

As permitted by law, notifications should include any known information regarding the incident and a general description of the activities or process in place to define and remediate the situation fully. Within 3 business days of the NIAGADS notification, the <u>Requester</u> agrees to submit to NIAGADS and the OER/DSPI Team a detailed written report including the date and nature of the event, actions taken or to be taken to remediate the issue(s), and plans or processes developed to prevent further problems, including specific information on timelines anticipated for action. The <u>Requester</u> agrees to provide any additional documentation requested by NIAGADS or the OER/DSPI Team on the incident,

including verifying that the remediation plans have been implemented. Repeated violations or unresponsiveness to NIH requests may result in further compliance measures affecting the Requester.

NIH, or another entity designated by NIH may, as permitted by law, also investigate any data security incident. <u>Approved Users</u> and their associates agree to support such investigations and provide any information, within the limits of applicable local, state, Tribal, and federal laws and regulations. In addition, <u>Requester</u> and <u>Approved Users</u> agree to work with the NIH to assure that plans and procedures that are developed to address identified problems are mutually acceptable and consistent with applicable law.

## 8. Terms of Access Violations

The Requester and Approved Users acknowledge that the NIH may terminate the DAR, including this Agreement and immediately revoke or suspend access to all controlled-access datasets subject to the NIH GDS Policy at any time if the Requester is found to be no longer in agreement with the principles outlined in the NIH GDS Policy, the terms described in this Agreement, the Genomic Data User Code of Conduct or the policies, principles and procedures of NIH. The Requester and Approved Users agree to notify NIAGADS and the OER/DSPI Team of any violations of the NIH GDS Policy, this Agreement, or the Genomic Data User Code of Conduct, hereinafter referred to as data management incidents (DMIs), within 24 hours of when the incident is identified. For OER/DSPI Team, notifications can be sent to DMI OER@mail.nih.gov. An exact copy of this documentation should be sent to NIAGADS at niagads@pennmedicine.upenn.edu. Repeated violations or unresponsiveness to NIH requests may result in further compliance measures affecting the Requester.

As permitted by law, notifications should include any known information regarding the incident and a general description of the activities, corrective actions, or process in place to define and remediate the situation fully. Within 3 business days of the notification(s), the <u>Requester</u> agrees to submit to NIAGADS and the OER/DSPI Team a detailed written report including the date and nature of the event, actions taken or to be taken to remediate the issue(s), and plans, preventive actions or processes developed to prevent future incidents, including specific information on timelines anticipated for action. The <u>Requester</u> agrees to provide documentation verifying that the remediation plans have been implemented. The <u>Requestor</u> agrees to incorporate any changes to corrective or preventive actions or to make any additional corrective and preventive actions requested by NIH. Repeated violations or unresponsiveness to NIH requests may result in further compliance measures affecting the <u>Requester</u>.

NIH, or another entity designated by NIH may, as permitted by law, also investigate any DMI. <u>Approved Users</u> and their associates agree to support such investigations and provide information, within the limits of applicable local, state, Tribal, and federal laws, and regulations. In addition, <u>Requester</u> and <u>Approved Users</u> agree to work with the NIH to assure that plans and procedures that are developed to address identified problems are mutually acceptable and consistent with applicable law.

## 9. Intellectual Property

By requesting access to dataset(s), the <u>Requester</u> and <u>Approved Users</u> acknowledge the intent of the NIH that anyone authorized for research access through the <u>DAR</u> follow the intellectual property (IP) principles as summarized below:

Achieving maximum public benefit is the ultimate goal of data distribution through the NIH
controlled-access data repositories. The NIH encourages broad use of NIH controlled-access data
that is consistent with a responsible approach to management of intellectual property derived
from downstream discoveries and expects that the Requestor and Approved User(s) adhere to
licensing practices consistent with the NIH Research Tools Policy.

The NIH considers these data as pre-competitive and urges <u>Approved Users</u> to avoid making IP claims derived directly from the dataset(s). It is expected that these NIH-provided data, and conclusions derived therefrom, will remain freely available, without requirement for licensing. However, the NIH also recognizes the importance of intellectual property in promoting the development of new therapies and products; as such, there is no restriction on development of commercial products resulting from the knowledge gained from the research project. Ownership of all intellectual property generated by activities under the research project will be governed by applicable patent law.

# 10. Dissemination of Research Findings and Acknowledgement of Controlled-Access Data Subject to the NIH GDS Policy

It is NIH's intent to promote the dissemination of research findings from use of controlled-access data subject to the NIH GDS Policy as widely as possible through scientific publication or other appropriate public dissemination mechanisms. <u>Approved Users</u> are strongly encouraged to publish their results in peer-reviewed journals and to present research findings at scientific meetings.

Approved Users agree to acknowledge the Submitting Investigator(s) who submitted data from the original study to NIAGADS, the primary funding organization that supported the Submitting Investigator(s), and NIAGADS, in all oral and written presentations, disclosures, and publications resulting from any analyses of controlled-access data obtained through the attached DAR. Approved Users further agree that the acknowledgment shall include the NIAGADS accession number to the specific version of the dataset(s) analyzed. A sample acknowledgment statement is provided for each dataset in the Addendum to this Agreement.

## Acknowledgment statement for use of data distributed by NIAGADS:

Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer's Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24AG041689), funded by the National Institute on Aging.

# 11. Research Use Reporting

To assure adherence to NIH GDS Policy, the <u>PI</u> agrees to provide annual <u>Progress Updates</u> as part of the annual <u>Project Renewal</u> or <u>Project Close-out</u> processes, prior to the expiration of the one (1) year data access period. The <u>PI</u> who is seeking renewal or close-out of a project agree to complete the appropriate online forms and provide specific information such as how the data have been used, including publications or presentations that resulted from the use of the requested dataset(s), a summary of any plans for future research use (if the <u>PI</u> is seeking renewal), any violations of the terms of access described within this Agreement and the implemented remediation, and information on any downstream intellectual property generated from the data. The <u>PI</u> also may include general comments regarding suggestions for improving the data access process in general. Information provided in the <u>Progress Updates</u> helps NIH evaluate program activities and may be considered by the NIH GDS governance committees as part of NIH's effort to provide ongoing stewardship of data sharing activities

subject to the NIH GDS Policy.

## 12. Non-Endorsement, Indemnification

The <u>Requester</u> and <u>Approved Users</u> acknowledge that although all reasonable efforts have been taken to ensure the accuracy and reliability of controlled-access data obtained through the attached <u>DAR</u>, the NIH, the NIAGADS Data Use Committee and <u>Submitting Investigator(s)</u> do not and cannot warrant the results that may be obtained by using any data included therein. NIH, NIA, NIAGADS, NADAC and all contributors to these datasets disclaim all warranties as to performance or fitness of the data for any particular purpose.

No indemnification for any loss, claim, damage, or liability is intended or provided by any party under this agreement. Each party shall be liable for any loss, claim, damage, or liability that said party incurs as a result of its activities under this agreement, except that NIH, as an agency of the United States, may be liable only to the extent provided under the Federal Tort Claims Act, 28 USC 2671 et seq.

#### 13. Termination and Data Destruction

A Project Close-out must be completed when an approved project is completed. Upon Project Close-out, the Requester and Approved Users agree to destroy all copies, versions, and Data Derivatives of the data retrieved from NIAGADS, on both local servers and hardware, and if Cloud Computing was used, delete the data and cloud images from Cloud Computing provider storage, virtual and physical machines, and databases in accord with the NIH Security Best Practices for Users of Controlled-Access Data. However, the Requester may retain only encrypted copies of the minimum data necessary at their institution to comply with institutional scientific data retention policy, law, and scientific transparency expectations for disseminated research results, and/or journal policies. A Requester who retains data for any of these purposes continues to be a steward of the data and is responsible for the management of the retained data in accordance with the NIH Security Best Practices for Users of Controlled-Access Data, and any institutional policies. Any retained data may only be used by the PI and Requester to support the findings (e.g., validation) resulting from the research described in the DAR that was submitted by the Requester and approved by NIH. The data may not be used to answer any additional research questions, even if they are within the scope of the approved <u>DAR</u>, unless the <u>Requester</u> submits a new <u>DAR</u> and is approved by NIH to conduct the additional research. If a Requester retains data for any of these purposes, the relevant portions of Terms 4, 5, 6, 7, 8, and 13 remain in effect after termination of this Data Use Certification Agreement. These terms remain in effect until the data is destroyed. In instances where NIH provides written notification that Data Derivatives should be transferred to a NIH controlledaccess data repository; the transfer must be completed prior to Project Close-out.

NIH may terminate this agreement at any time for any reason at its discretion with written notice to the <u>Requestor</u>.

## 14. Definitions

**Approved User:** A user approved by the relevant Data Access Committee(s) to access one or more datasets for a specified period of time and only for the purposes outlined in the <u>Principal Investigator</u> (PI)'s approved Research Use Statement. The <u>Information Technology</u> (IT) Director indicated on the Data Access Request, as well as any staff members and trainees under the direct supervision of the <u>PI</u> are also Approved Users and must abide by the terms laid out in the Data Use Certification Agreement.

**Collaborator:** An individual who is not under the direct supervision of the <u>PI</u> (e.g., not a member of the PI's laboratory) who assists with the <u>PI</u>'s research project involving controlled-access data subject to the NIH GDS Policy. Internal <u>Collaborators</u> are employees of the <u>Requester</u> and work at the same location/campus as the <u>PI</u>. External <u>Collaborators</u> are not employees of the <u>Requester</u> and/or do not work at the same location as the <u>PI</u>, and consequently must be independently approved to access controlled-access data subject to the NIH GDS Policy.

**Cloud Computing:** The National Institute for Standards and Technology defines cloud computing as a model for enabling ubiquitous, convenient, on-demand network access to a shared pool of configurable computing resources (e.g., networks, servers, storage, applications, and services) that can be rapidly provisioned and released with minimal management effort or service provider interaction. For more information see <a href="NIST Special Publication 800-145">NIST Special Publication 800-145</a>.

**Cloud Service Provider (CSP):** A company or institution that offers some component of <u>cloud computing</u> to other businesses or individual, typically Infrastructure as a Service (IaaS), Software as a Service (SaaS) or Platform as a Service (PaaS), as defined by the National Institute of Standards and Technology. For more information see NIST Special Publication 800-145.

**Data Access Request (DAR):** A request submitted by a <u>Principal Investigator</u> to a NIH Data Access Committee for access to controlled-access data from a NIH-designated data repository. The DAR is signed by the <u>PI</u> requesting the data and their <u>Institutional Signing Official</u>.

**Data Derivative:** Data derived from controlled-access datasets obtained from NIH-designated data repositories. Examples of derived data include imputed datasets and single nucleotide polymorphisms, or any data explicitly designated as <u>Data Derivatives</u> by NIH.

**Data Use Certification (DUC) Agreement:** An agreement between the <u>Approved User</u>, the <u>Requester</u>, and the University of Pennsylvania regarding the terms associated with access of controlled-access datasets subject to the NIH GDS Policy and the expectations for use of these datasets.

**Genomic Data User Code of Conduct:** Key principles and practices agreed to by all research investigators requesting access to controlled-access data subject to the NIH GDS Policy. The elements within the <u>Genomic Data User Code of Conduct</u> reflect the terms of access in the <u>Data Use Certification Agreement</u>.

Information Technology (IT) Director: An Approved User who is generally a senior IT official of the Requester with the necessary expertise and authority to affirm the IT capacities at the Requester. The IT Director is expected to have the authority and capacity to ensure that the NIH Security Best Practices for Users of Controlled-Access Data and the Requester's IT security requirements and policies are followed by all of the Requester's Approved Users.

**Institutional Certification:** Certification by the <u>Submitting Institution</u> that delineates, among other items, the appropriate research uses of the data and the uses that are specifically excluded by the relevant informed consent documents. Further information may be found <u>here</u>.

**Institutional Signing Official:** The label, "Signing Official," is used in conjunction with the <u>NIH eRA</u> <u>Commons</u> and refers to the individual that has institutional authority to legally bind the institution in

grants administration matters. The individual fulfilling this role may have any number of titles in the institution but is typically located in its Office of Sponsored Research or equivalent.

NIAGADS Alzheimer's Disease and Related Dementias (ADRD) Data Access Committee (NADAC): A committee made up of NIH staff that reviews Data Access Request applications made by Principal Investigators.

**NIAGADS** Data Use Committee (DUC): The Data Use Committee (DUC) is independently formed by NIA. The DUC reviews all plans to return derived/secondary data to NIAGADS.

**Principal Investigator (PI):** An investigator who is a permanent employee of their institution at a level equivalent to a tenure-track professor or senior scientist with responsibilities that most likely include laboratory administration and oversight. Additionally, the investigator has the authority to ensure those that they directly supervise adhere to the terms of access in this agreement.

**Progress Update:** Information included with the annual <u>Data Access Request</u> (DAR) renewal or Closeout summarizing the analysis of controlled-access datasets obtained through the <u>DAR</u> and any publications and presentations derived from the work.

**Project Close-out:** Termination of a research project that used controlled-access data from an NIH-designated data repository (e.g., NIAGADS) and confirmation of data destruction when the research is completed and/or discontinued. The project close-out process is completed by NIAGADS.

**Project Renewal:** Renewal of a <u>Pl</u>'s access to controlled-access datasets for a previously approved project.

**Requester:** The home institution or organization of the <u>Approved User</u> that applies to NIAGADS for access to controlled-access data subject to the NIH GDS Policy.

**Submitting Institution:** An organization who submitted a genomic dataset to an NIH-designated data repository (e.g., NIAGADS).

**Submitting Investigator:** An investigator who submitted a genomic dataset to an NIH designated data repository (e.g., NIAGADS).

**Third-party IT system:** A collection of computing and/or communications components and other resources that support one or more functional objectives of an organization.